Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Edris Badreddin | Chief Operating Officer | Mar 03 '25 | Sale | 54.23 | 20,000 | 1,084,592 | 169,712 | Mar 05 06:33 PM | | Islam Saqib | Chief Executive Officer | Mar 03 '25 | Sale | 54.24 | 49,000 | 2,657,656 | 954,869 | Mar 05 06:32 PM | | Islam Saqib | Chief Executive Officer | Feb 20 '25 | Sale | 60.30 | 29,328 | 1,768,401 | 1,034,625 | Feb 24 06:58 PM | | Ashar Bhavesh | Chief Commercial Officer | Feb 20 '25 | Sale | 61.19 | 1,016 | 62,168 | 62,053 | Feb 24 06:58 PM | | LYNCH DANIEL | Director | Feb 20 '25 | Sale | 60.22 | 47,600 | 2,866,534 | 82,944 | Feb 24 06:57 PM | | Bhavesh Ashar | Officer | Feb 20 '25 | Proposed Sale | 61.38 | 16,090 | 987,604 | | Feb 20 04:18 PM | | Islam Saqib | Chief Executive Officer | Feb 14 '25 | Sale | 59.92 | 10,672 | 639,490 | 1,063,953 | Feb 19 04:50 PM | | LYNCH DANIEL | Director | Feb 14 '25 | Sale | 60.00 | 400 | 24,000 | 130,544 | Feb 19 04:49 PM | | DANIEL LYNCH | Director | Feb 14 '25 | Proposed Sale | 58.59 | 48,000 | 2,812,320 | | Feb 14 04:21 PM | | Pichl Daniel | Chief People Officer | Feb 10 '25 | Option Exercise | 27.64 | 29,750 | 822,290 | 80,512 | Feb 12 08:01 PM | | Pichl Daniel | Chief People Officer | Feb 10 '25 | Sale | 54.36 | 29,750 | 1,617,329 | 50,762 | Feb 12 08:01 PM | | LYNCH DANIEL | Director | Feb 10 '25 | Sale | 54.46 | 175,000 | 9,530,351 | 130,944 | Feb 12 07:59 PM | | Islam Saqib | Chief Executive Officer | Feb 10 '25 | Sale | 53.30 | 48,000 | 2,558,237 | 1,002,502 | Feb 12 07:58 PM | | Hambleton Julie | Director | Feb 10 '25 | Option Exercise | 32.27 | 13,774 | 444,487 | 17,869 | Feb 12 07:57 PM | | Hambleton Julie | Director | Feb 10 '25 | Sale | 53.01 | 13,774 | 730,207 | 4,095 | Feb 12 07:57 PM | | Edris Badreddin | Chief Operating Officer | Feb 10 '25 | Sale | 53.13 | 30,000 | 1,593,795 | 189,712 | Feb 12 07:55 PM | | Saqib Islam | Officer | Feb 10 '25 | Proposed Sale | 53.30 | 137,000 | 7,301,552 | | Feb 10 04:38 PM | | DANIEL LYNCH | Director | Feb 10 '25 | Proposed Sale | 40.28 | 175,000 | 7,049,000 | | Feb 10 04:29 PM | | Daniel Pichl | Officer | Feb 10 '25 | Proposed Sale | 54.36 | 29,750 | 1,617,329 | | Feb 10 04:13 PM | | Julie Hambleton | Board Member | Feb 10 '25 | Proposed Sale | 53.01 | 13,774 | 730,207 | | Feb 10 04:09 PM | | Badreddin Edris | Officer | Feb 10 '25 | Proposed Sale | 41.00 | 50,000 | 2,050,000 | | Feb 10 04:08 PM | | Edris Badreddin | Chief Operating Officer | Dec 03 '24 | Sale | 41.97 | 20,000 | 839,336 | 209,600 | Dec 05 06:14 PM | | Islam Saqib | Chief Executive Officer | Dec 02 '24 | Sale | 41.37 | 49,000 | 2,027,357 | 1,014,368 | Dec 04 04:23 PM | | Islam Saqib | Chief Executive Officer | Sep 03 '24 | Sale | 40.57 | 49,000 | 1,988,033 | 1,063,368 | Sep 04 04:05 PM | | Edris Badreddin | Chief Operating Officer | Sep 03 '24 | Sale | 40.65 | 20,000 | 812,954 | 229,600 | Sep 04 04:05 PM | | Badreddin Edris | Officer | Sep 03 '24 | Proposed Sale | 41.78 | 50,000 | 2,089,000 | | Sep 03 04:09 PM | | Saqib Islam | Officer | Sep 03 '24 | Proposed Sale | 41.58 | 146,000 | 6,070,680 | | Sep 03 04:07 PM |
|
